Abstract
Pathological bone loss always reflects enhanced net osteoclastic activity. Recognition and binding of the receptor activator of NF-κB (RANK) by RANK ligand (RANKL) is the key osteoclastogenic event, and the signaling cascades induced by this reaction therefore contain potential anti-osteoporosis therapeutic targets. A study reported in this issue of the JCI documents that a pivotal component of RANKL/RANK-mediated osteoclast recruitment involves sequential induction of the transcription factors c-Jun and nuclear factor of activated T cells 2 (see the related article beginning on page 475).
Original language | English |
---|---|
Pages (from-to) | 463-465 |
Number of pages | 3 |
Journal | Journal of Clinical Investigation |
Volume | 114 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2004 |